Prurigo Nodularis Epidemiology Summary
- Prurigo nodularis primarily affects middle-aged and older adults and is associated with a substantial multidimensional disease burden. The condition is particularly common among individuals aged 50 years and older and frequently occurs in patients with other chronic conditions, including atopic dermatitis, kidney disease among other disorders. The persistent itch–scratch cycle can result in numerous hyperkeratotic nodules, sleep disruption and impaired quality of life, making it a clinically burdensome condition beyond its cutaneous manifestations.
- According to Kwatra et al. (2024), prurigo nodularis corresponds to a standardized prevalence of approximately 52.9 cases per 100,000 population, according to prevalence estimates, highlighting the substantial population affected by this chronic pruritic skin disease.
- A major unmet need in the prurigo nodularis is the underdiagnoses and delayed recognition of the disease, driven by its overlap with other chronic pruritic dermatoses and the absence of standardized epidemiological assessment in many countries. This can result in patients remaining undiagnosed for prolonged periods, creating a substantial gap between the true disease burden and the diagnosed and treated patient population, and highlighting the need for improved disease recognition, standardized diagnosis, and systematic epidemiological surveillance.
DelveInsight’s “Prurigo Nodularis – Epidemiology, Forecast – 2036” report delivers an in depth understanding of prurigo nodularis, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
Geography Covered
North America: The United States
Europe: Germany, France, Italy, Spain and the United Kingdom
Asia-Pacific: Japan
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2025 |
|
Geographies Covered |
|
|
Prurigo Nodularis Epidemiology Segmentation Analysis |
Patient Burden Assessment
|
Prurigo Nodularis Understanding and Treatment Algorithm
Prurigo Nodularis Overview and Diagnosis
Prurigo nodularis is a chronic skin disorder characterized by the appearance of multiple, firm, itchy nodules on the skin, which are often the result of repetitive scratching or rubbing. These nodules can range in size and are typically found on areas like the arms, legs, back, and chest. The primary symptom of prurigo nodularis is intense pruritus (itching), which causes individuals to scratch, further aggravating the lesions and leading to thickened, scaly, or hyperpigmented skin. In severe cases, the nodules can ulcerate or become infected due to ongoing friction and trauma.
The diagnosis of prurigo nodularis is primarily clinical, based on the characteristic appearance of itchy, raised nodules on the skin. A healthcare provider will typically assess the patient's medical history, including any underlying conditions such as atopic dermatitis, kidney disease, or mental health issues that may contribute to the development of prurigo nodularis. A physical examination is conducted to evaluate the number, size, and location of the nodules, which are typically found on the arms, legs, and torso. In some cases, a skin biopsy may be performed to rule out other conditions, such as skin infections or malignancies, as the nodules may resemble other dermatologic disorders. Laboratory tests may also be conducted to assess for underlying systemic conditions, particularly in patients with suspected renal or hepatic disease.
Further details related to country-based variations are provided in the report…
Prurigo Nodularis Epidemiology
Key Findings from Prurigo Nodularis Epidemiological Analysis and Forecast
- The US contributed to the largest diagnosed prevalent population of prurigo nodularis, acquiring more than 40% of the 7MM in 2025.
- According to Kwatra et al. (2024), it is reported that the prevalence of prurigo nodularis ranges approximately 52.9 cases per 100,000 population in the US.
- The highest number of cases were found in the 65 years age group (~46%), followed by 25–44 year age group while the lowest number of cases was observed in <15 years age group.
- According to Kwatra et al. (2025), reported prevalence of prurigo nodularis was 3.32 per 10,000 (0.03%) in Germany.
- As per Igarashi et al. (2025), the prevalence of prurigo nodularis in Japan was estimated at 41 cases per 100,000 population.
Key Opinion Leaders (KOLs) Views
To keep up with prurigo nodularis dynamic epidemiology trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the prurigo nodularis epidemiology, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.
DelveInsight’s analysts connected with 8+ KOLs to gather insights at country level. Center such as Massachusetts General Hospital, University of California San Francisco Medical Center, Institute for Health Services Research in Dermatology and Nursing, University Hospitals Cleveland Medical Center, Miller School of Medicine and Miami Itch Center and University of Maryland etc. were contacted.
Their opinion helps understand, validate, highlight and provide epidemiological context in prurigo nodularis.
|
Region |
Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) |
|
United States |
“Prurigo nodularis in the United States predominantly affects older adults. The condition is also associated with substantial comorbidity burden, suggesting that its epidemiological impact extends beyond the dermatological manifestations. Differences in case identification and diagnostic patterns across healthcare settings may contribute to under recognition of the overall disease burden.” |
|
Germany |
“The epidemiological burden of prurigo nodularis may be influenced by challenges in recognizing and accurately diagnosing the disease, as its clinical presentation can overlap with other conditions, particularly during the early stages of disease. The absence of a definitive diagnostic test and reliance on clinical assessment may further contribute to variability in disease identification across healthcare settings. Consequently, some patients may remain undiagnosed or be assigned alternative dermatological diagnoses, potentially leading to underestimation of the true patient population.” |
Note: Detailed assessment of KOL Views will be provided in the full report on prurigo nodularis
Scope of the Report
- The report covers a segment of key events, an executive summary, a descriptive overview of prurigo nodularis, explaining its causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Prurigo nodularis Patient Population Forecast
Report Key Strengths
- Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
- Artificial Intelligence (AI)-Enabled Market Research Report
- 11-Year Forecast
FAQs
- What are the disease risks, burdens, and unmet needs of prurigo nodularis?
- What will be the growth opportunities across the 7MM concerning the patient population with prurigo nodularis?
- What is the prurigo nodularis prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
- What is the historical and forecasted prurigo nodularis patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on prurigo nodularis burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
- Clear methodology, validated assumptions, and data-driven rationale to assess the prurigo nodularis epidemiology analysis and patient population trends.
